These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 15996325)

  • 1. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
    Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
    O'Meara AT; Sevin BU
    Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay-].
    Kurbacher CM; Mallmann P; Kurbacher JA; Hübner H; Krebs D
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):70-8. PubMed ID: 8647362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
    Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
    Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
    Neubauer H; Stefanova M; Solomayer E; Meisner C; Zwirner M; Wallwiener D; Fehm T
    Anticancer Res; 2008; 28(2A):949-55. PubMed ID: 18507041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
    Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.
    Sharma S; Neale MH; Di Nicolantonio F; Knight LA; Whitehouse PA; Mercer SJ; Higgins BR; Lamont A; Osborne R; Hindley AC; Kurbacher CM; Cree IA
    BMC Cancer; 2003 Jul; 3():19. PubMed ID: 12841853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
    Shi W; Gu M; Liang L
    Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of a micromethod in ovarian cancer chemosensitivity testing in vitro].
    Liu S; Qian X; Peng Z; Wang H
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 34(2):298-9, 312. PubMed ID: 12947719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
    Qian XL; Peng ZL; Liu SL
    Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements.
    Kurbacher CM; Cree IA
    Methods Mol Med; 2005; 110():101-20. PubMed ID: 15901931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples.
    Ng TY; Ngan HY; Cheng DK; Wong LC
    Gynecol Oncol; 2000 Mar; 76(3):405-8. PubMed ID: 10684718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
    Gao YT; Wu LY; Zhang W; Zhao D; Li N; Tian HM; Wang XB; Li M; Sun YC; Li N; Li XG
    Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):358-63. PubMed ID: 24016479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay.
    Qi CJ; Ning YL; Zhu YL; Min HY; Ye H; Qian KQ
    Arch Pharm Res; 2009 Dec; 32(12):1737-42. PubMed ID: 20162402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.
    Moon YW; Choi SH; Kim YT; Sohn JH; Chang J; Kim SK; Park MS; Chung KY; Lee HJ; Kim JH
    Cancer; 2007 May; 109(9):1829-35. PubMed ID: 17366594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
    Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
    Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of lung resistant-related protein in ovarian cancer and its clinical significance].
    Qian XL; Peng ZL; Liu SL; Wang H; Ni J
    Ai Zheng; 2002 Dec; 21(12):1332-4. PubMed ID: 12520742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay.
    Hunter EM; Sutherland LA; Cree IA; Dewar JA; Preece PE; Wood RA; Linder D; Andreotti PE
    Eur J Surg Oncol; 1993 Jun; 19(3):242-9. PubMed ID: 8314382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.